ArticleHepatology international2026
Plasma proteomic signatures of biological aging and metabolic dysfunction-associated steatotic liver disease risk: a prospective cohort study.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBiological aging is associated with incident metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying proteomic mechanisms remain largely unknown. This study aimed to systematically characterize the plasma proteomic landscape and identify specific biomarkers that mediate the aging-MASLD axis.
methodsWe analyzed the associations between four multi-dimensional biological aging indicators (telomere length, frailty index, Klemera-Doubal method biological age, and phenotypic age), 2911 plasma proteins, and incident MASLD among 52,131 UK Biobank participants. A rigorous two-stage analytical pipeline, integrating multivariable linear and elastic net regression, was applied to screen robust aging-related proteins. Cox proportional hazard regression models and mediation analyses were employed to assess their roles in MASLD risk, followed by comprehensive tissue and functional enrichment analyses to elucidate underlying biological mechanisms.
resultsDuring a median follow-up of 13.60 years, 762 participants developed MASLD. All biological aging indicators were significantly linked to MASLD incidence. We identified distinct proteomic signatures for these biological aging indicators. Furthermore, multiple proteins significantly mediated the corresponding association, explaining 0.5 to 50.7% of the risk. Notably, 769 unique mediators were identified, anchored by a core signature of five shared proteins (AXL, CCL19, CPM, REN, and TNFRSF11B) across all four indicators. Enrichment analyses revealed a multi-organ origin (predominantly lung, adipose tissue, and arteries), highlighting the dominance of immune-inflammatory pathways.
conclusionsPlasma proteins partially mediate the increased MASLD risk driven by biological aging. These findings underscore the roles of systemic immune-inflammatory signaling, providing biomarkers for early risk stratification and potential novel therapeutic targets for aging-associated hepatic pathology.
Indexed as
Identifiers
42842104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.